Zyprexa vs. Geodon
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly claims long-term use of its atypical antipsychotic Zyprexa (olanzapine) yields greater efficacy than Pfizer's Geodon (ziprasidone), based on a 28-week, head-to-head study presented March 30 at the International Congress on Schizophrenia Research. The 548-patient, double-blind, flexible-dose study found long-term Zyprexa resulted in significantly better improvement for the study's primary endpoint, the Positive and Negative Syndrome Scale (p<0.001), and significantly more patients responded positively to treatment (58.6% vs. 42.5%). A study poster reports that "although [Zyprexa] patients had greater weight gain and elevated lipids, [Geodon] patients experienced significantly more adverse events," and a greater proportion of Geodon patients required a dose reduction due to side effects (26.9% vs. 14.8%
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.